Symbicort® COPD (budesonide/formoterol)

Symbicort® (budesonide/formoterol) Turbohaler® and Symbicort® pMDI are combinations of an inhaled corticosteroid and a long-acting β2-agonist 

References

  1. Symbicort Turbohaler 200/6, Inhalation powder. Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/medicine/4821. last accessed February 2018
  2. Symbicort Turbohaler 400/12, Inhalation powder. Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/medicine/11882. last accessed February 2018. 
  3. Symbicort 200/6, Pressurised inhalation, suspension. Summary of Product Characteristics Available from: https://www.medicines.org.uk/emc/medicine/32036. last accessed February 2018.
  4. Szafranski W et al. Eur Respir J 2003;21:74–81.
  5. Partridge MR et al. Ther Adv Respir Dis 2009;3:147–157.   
  6. Roche N et al. Resp Res 2013;14:112.
  7. Partridge MR et al. Eur Resp J 2010;36:96–104.
  8. Selroos O et al. Treat Respir Med 2006;5:305–315.
  9. Demoly P et al. Respir Med 2014;108:1195–1203.
  10. de Boer A et al. Eur J Pharm Biopharm 2015;96:143–151.
  11. https://www.mims.co.uk/drugs/respiratory-system/asthma-copd/symbicort-pmdi. last accessed February 2018.
  12. Stone RA et al. COPD: Who cares matters. National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Clinical audit of COPD exacerbations admitted to acute units in England and Wales 2014. National clinical audit report. London: RCP, February 2015.
  13. Suissa S et al. Thorax 2012;67:957–963.
  14. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: http://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf. last accessed February 2018. 
  15. Vogelmeier CF et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD executive summary. 2017 1440–1843.

COPD: GB-10608

Date of preparation February 2018